arrow
A

Amer M. Zeidan

Yale University
H指数:56
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Implications of TP53 mutations in patients with higher risk myelodysplastic syndromes (MDS) who received hypomethylating agent therapy: an analysis from the VALIDATE database of the International Consortium for MDS

TP53突变在高风险骨髓增生异常综合征(MDS)患者接受去甲基化药物治疗后的影响:来自国际MDS联盟VALIDATE数据库的分析

2026-11-140
OAAI
Myelodysplastic syndromes/neoplasms presenting with isolated thrombocytopenia: a poorly understood pathophysiology, difficult to diagnose, and challenging to treat entity

骨髓增生异常综合征/新生物表现为孤立性血小板减少症:一种病理生理机制尚不明确、诊断困难且治疗具有挑战性的实体

2026-10-240
OA
Phase 1 dose escalation and expansion trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein SL-172154 (SIRPα-Fc-CD40L) in patients with higher-risk myelodysplastic syndrome or acute myeloid leukemia

I期剂量递增和扩展试验:双特异性CD47抑制剂和CD40激动剂Fc融合蛋白SL-172154(SIRPα-Fc-CD40L)在具有高风险骨髓增生异常综合征或急性髓系白血病患者中的应用

Cancer
IF5.1
2026-10-050
OAAI
The PRIME trial: An investigator-initiated, multicentre, phase II study of the poly(ADP-ribose) polymerase inhibitor olaparib in isocitrate dehydrogenase (IDH)-mutated relapsed/refractory acute myeloid leukaemia and myelodysplastic syndromes

PRIME试验:一项由研究者发起的多中心II期研究,评估聚(ADP-核糖)聚合酶抑制剂奥拉帕利在异柠檬酸脱氢酶(IDH)突变复发/难治性急性髓系白血病和骨髓增生异常综合征中的应用

2026-09-060
OAAI
Choice of hypomethylating agent for newly diagnosed TP53-mutant acute myeloid Leukemia: a COMMAND registry study
Leukemia
IF13.4
2026-08-310
PRE
Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients With Higher-Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS)

基于低甲基化制剂治疗的反应对高风险骨髓增生异常综合征/肿瘤患者生存结局的影响:考虑基线临床-分子风险和移植状态的国际骨髓增生异常综合征联盟(icMDS)分析

2026-08-280
PRE
Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax—an analysis from the International Consortium for MDS (icMDS) VALIDATE database

高风险骨髓增生异常综合征/新生物患者接受去甲基化药物+维奈克拉治疗后的结局分析——国际骨髓增生异常综合征(icMDS)VALIDATE数据库分析

2026-06-290
OAAI
Prognostic Score for Myelodysplastic Syndromes Based on Molecular Evolution

基于分子演化的骨髓增生异常综合征预后评分

2026-05-262
PRE
Clinical strategies for leukemia management: Recommendations from the Bridging the Gaps in Hematology Oncology Consensus Conference 2025

白血病管理临床策略:2025年血液肿瘤学弥合差距共识会议的建议

2026-05-010
PRE
Association between treatment-emergent cytopenias and clinical responses to imetelstat in lower-risk myelodysplastic syndromes

治疗相关细胞减少症与低危骨髓增生异常综合征患者对imetelstat临床反应之间的关联

2026-04-070
OAAI
Decitabine-cedazuridine in patients with MDS and TP53 mutations

地西他滨-西达佐鲁定在伴TP53突变的患者中的研究

2025-11-140
OAAI
Clinical outcomes and safety in patients with lower-risk myelodysplastic syndromes treated with imetelstat: Substudy of the phase 3 IMerge trial

低危骨髓增生异常综合征患者接受伊米替列stat治疗后的临床疗效与安全性:IMerge三期试验的子研究

2025-11-010
OAAI